Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07084831 | A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia | PHASE3 | NOT YET_RECRUITING | 171 | — | — | Jan 1, 2027 | Jul 1, 2029 | May 13, 2026 | 16 | Austria, Belgium +8 |
The within-participant change in the Brief Assessment of Cognition in Schizophrenia composite cognitive score from baseline to follow-up after 24 weeks. Higher score means better cognition. There is no max score, as the tests have different scoring methods (number correct, reaction time).
| Arm | Type | Description |
|---|---|---|
| Xanomeline/trospium | EXPERIMENTAL | Xanomeline/trospium that is provided to all participants |
| Name | Type | Description |
|---|---|---|
| Xanomeline/trospium | DRUG | Participants will receive oral xanomeline/trospium during the trial (target dose 125/30 BID). |
Inclusion criteria: 1. Be between 18 and 55 years of age. 2. Be willing and able to provide informed consent, after the nature of the study has been fully explained. This includes being able to understand the locally approved informed consent (and information letter) in the local language. 3. Have ...